financetom
Business
financetom
/
Business
/
Market Chatter: Goldman Sachs Shareholders Receive ISS Recommendation for Independent Board Chair
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: Goldman Sachs Shareholders Receive ISS Recommendation for Independent Board Chair
Apr 3, 2024 3:43 PM

06:18 PM EDT, 04/03/2024 (MT Newswires) -- Goldman Sachs Group ( GS ) shareholders are being urged by Institutional Shareholders Services to choose an independent board chair at its annual meeting later this month, Reuters reported Wednesday, citing an ISS memo.

Goldman board, however, is recommending investors vote against the proposal on April 24, saying they already "take very seriously their fiduciary obligation to act in the best interests of our firm and our shareholders," according to proxy statement.

Goldman Sachs ( GS ) shareholders overwhelmingly rejected a similar proposal at the company's 2023 annual meeting, with the proposal for independent chair garnering only 40 million shares out of total outstanding. Shareholders have put forward proposals to select an independent chair at the company since at least 2021.

ISS also recommended a vote in favor of all the director nominees, Reuters reported.

Goldman did not immediately respond to a request for comments by MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 414.9, Change: +0.9, Percent Change: +0.22

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Point72 Asset Management, L.P. Reports 6.2% Passive Stake In ATYR Pharma As Of Oct 14 - SEC Filing
BRIEF-Point72 Asset Management, L.P. Reports 6.2% Passive Stake In ATYR Pharma As Of Oct 14 - SEC Filing
Oct 17, 2024
Oct 15 (Reuters) - aTyr Pharma Inc ( ATYR ): * POINT72 ASSET MANAGEMENT, L.P. REPORTS 6.2% PASSIVE STAKE IN ATYR PHARMA AS OF OCT 14 - SEC FILING Source text for Eikon: Further company coverage: ...
Fulton Financial Q3 Operating Net Income, Revenue Rise
Fulton Financial Q3 Operating Net Income, Revenue Rise
Oct 17, 2024
05:05 PM EDT, 10/15/2024 (MT Newswires) -- Fulton Financial ( FULT ) reported Q3 operating net income late Tuesday of $0.50 a share, up from $0.43 a year earlier. Analysts surveyed by Capital IQ expected $0.44. Revenue in the three months ended Sept. 30, expressed as the sum of net interest income and total noninterest income, rose to $317.7 million...
UroGen Pharma Says US FDA Accepts New Drug Application for Bladder Cancer Treatment
UroGen Pharma Says US FDA Accepts New Drug Application for Bladder Cancer Treatment
Oct 17, 2024
05:04 PM EDT, 10/15/2024 (MT Newswires) -- UroGen Pharma ( URGN ) said Tuesday the US Food and Drug Administration accepted the new drug application for UGN-102 as an intravesical solution to treat low-grade intermediate-risk non-muscle invasive bladder cancer. The FDA has set a Prescription Drug User Fee Act target action date of June 13, 2025, the company said. The...
NovoCure Says US FDA Approves Optune Lua to Treat Lung Cancer; Shares Jump After Hours
NovoCure Says US FDA Approves Optune Lua to Treat Lung Cancer; Shares Jump After Hours
Oct 17, 2024
05:05 PM EDT, 10/15/2024 (MT Newswires) -- NovoCure ( NVCR ) said late Tuesday the US Food and Drug Administration has approved its Optune Lua device to treat adults with metastatic non-small cell lung cancer. The approval is for the simultaneous use of Optune Lua with PD-1/PD-L1 inhibitors or docetaxel in lung cancer patients who have progressed on or after...
Copyright 2023-2026 - www.financetom.com All Rights Reserved